广东东阳光科技控股股份有限公司 二○二四年年度股东大会会议资料 600673 广东东阳光科技控股股份有限公司 2025 年 5 月 广东东阳光科技控股股份有限公司 2024 年年度股东大会文件目录 | 2024 年年度股东大会议程 | | 3 | | | --- | --- | --- | --- | | 议案一：公司 | 2024 年度报告及摘要 | | 5 | | 议案二：公司 | 2024 年度董事会工作报告 | | 6 | | 议案三：公司 | 2024 年度监事会工作报告 | | 18 | | 议案四：公司 | 2024 年度财务决算报告 | | 21 | | 议案五：关于 | 2024 年度利润分配的方案 | | 22 | | 议案六：关于 | 2025 年度日常关联交易的议案 | | 23 | | | 议案七：关于续聘天健会计师事务所（特殊普通合伙）为本公司 | 2025 | 年度财务 | | 审计和内控审计机构的议案 | | | 25 | | 议案八：关于 | 2025 | 年度对外担保额度预计的议案 | 28 | | 议案九：关于 | 2025 | 年度开展票据池业务的议案 | 31 | | ...

广东东阳光科技控股股份有限公司2025 年第一季度报告 证券代码：600673 证券简称：东阳光 债券代码：242444 债券简称：25 东科 01 广东东阳光科技控股股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同 期增减变动幅度(%) | | --- | --- | --- | --- | | 营业收入 | 3,346,763,925.04 | 2,829,630,561.75 | 18.28 | | 归属于上市公司股东的净利润 | 278,042, ...

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 2025-32 号 | | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | 广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东之一致行动人宜昌东阳光药业股份有限公司（以下简称"宜昌 药业股份"）持有本公司股份 545,023,350 股，占公司总股本的 18.08%；截至本 次股份质押完成后，宜昌药业股份持有本公司股份累计质押数量 521,500,000 股， 占其持股数量的 95.68%。 截至本公告披露日，公司控股股东深圳市东阳光实业发展有限公司（以 下简称"深圳东阳光实业"）累计质押股数数量为 561,798,054 股，占其持股数 量的 90.96%；控股股东及其一致行动人累计质押股数数量为 1,214,388,597 股， 占合计持股数量比例为 76.47%。 三、上市公司控股股东股 ...

Core Viewpoint - The recent surge in the stock price of Dongyangguang Changjiang Pharmaceutical is primarily driven by the shift of funds towards more certain high-quality targets amid increasing external market volatility [1][3]. Group 1: Stock Performance and Market Sentiment - From April 8 to April 15, Dongyangguang Changjiang Pharmaceutical experienced a maximum stock price increase of 37.67%, demonstrating strong risk resistance and defensive attributes [1]. - Northbound capital has consistently increased its holdings in Dongyangguang Changjiang Pharmaceutical, raising its shareholding from 11.99% on September 11 last year to 26.65% by April 14 this year, with a market value exceeding 2 billion HKD [1][4]. Group 2: Merger and Acquisition Progress - The company announced updates regarding its merger with Dongyangguang Pharmaceutical, indicating that it has met one of the three prerequisites for the final merger, having received approval from the National Development and Reform Commission [4]. - The merger is expected to lead Dongyangguang Pharmaceutical towards a potential market capitalization of 100 billion [3]. Group 3: Innovation and R&D Capabilities - Dongyangguang Pharmaceutical has established a comprehensive R&D platform with over 1,200 professionals, covering the entire lifecycle of drug development, including target validation, early discovery, and clinical research [9]. - The company has received approval for 147 drugs globally and has over 100 drugs in development, including 45 first-class innovative drugs [7]. Group 4: Financial Investments and Market Position - In 2024, the company's R&D investment is projected to reach 493 million, a significant increase of 156.62% year-on-year, supporting steady progress in its differentiated innovation pipeline [11]. - The company has signed a milestone licensing agreement worth 938 million USD with Apollo Therapeutics for its dual-specific fusion protein, HEC88473, marking a record in domestic BD transaction amounts for GLP-1/FGF21 dual-function molecules [11]. Group 5: Strategic Collaborations and AI Integration - Dongyangguang Pharmaceutical is advancing its AI-driven drug development, having received approval for its first small molecule innovative drug, HEC169584, for clinical trials in non-alcoholic fatty liver disease [13]. - The collaboration with Huawei Cloud aims to optimize drug molecular properties and structures, significantly enhancing drug discovery efficiency [13]. Group 6: Market Outlook - As the listing timeline approaches, Dongyangguang Pharmaceutical is expected to attract more capital in the current "self-controllable" market cycle, potentially leading to a valuation increase and providing investors with diverse investment options [14].

Group 1 - The company, Shandong Sunshine Holiday International Travel Agency Co., Ltd., has announced a new regulation regarding the management of seals used by its subsidiaries, stating that all seals must be uniformly supervised by the head office starting from February 8, 2025 [1] - Subsidiaries are required to apply for and register the use of their seals with the head office before they can be used, emphasizing the need for centralized control [1] - A previous notification was sent on February 8, 2025, via WeChat to the store managers, indicating that all seals were to be retrieved and managed by the head office, but several subsidiaries have not complied with this directive [1][2] Group 2 - A list of subsidiaries that have not executed the seal management directive includes various branches located in Jinan, Qufu, and other cities, indicating a widespread issue with compliance [2] - The subsidiaries listed include Jinan Lixia Branch, Jinan Branch, and others, highlighting the need for the head office to enforce its regulations more effectively [2] - The announcement reflects the company's efforts to strengthen internal controls and ensure proper governance across its subsidiaries [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong performance relative to the market [7]. Core Insights - The company reported a significant increase in revenue and net profit for 2024, driven by rising refrigerant prices and successful production of layered foil projects [7]. - The first quarter of 2025 is expected to show a slight outperformance, with net profit projected to grow by 156.17% to 227.05% year-on-year [7]. - The company is well-positioned in the refrigerant market, with a favorable outlook for 2025 due to supply-demand dynamics and price increases [7]. - Strategic partnerships in liquid cooling solutions and humanoid robotics are expected to enhance growth prospects [7]. - The layered foil capacitor project is set to lead industry upgrades, with significant customer engagement and production capacity expansion [7]. Financial Data and Profit Forecast - Total revenue is projected to grow from 10,854 million in 2023 to 16,965 million by 2027, with a compound annual growth rate (CAGR) of approximately 10.1% [3][9]. - Net profit is expected to increase from -294 million in 2023 to 2,137 million by 2027, reflecting a substantial recovery and growth trajectory [3][9]. - Earnings per share (EPS) is forecasted to rise from -0.10 in 2023 to 0.71 in 2027, indicating improved profitability [3][9]. - The gross margin is anticipated to improve from 11.1% in 2023 to 23.6% in 2027, showcasing enhanced operational efficiency [3][9]. - Return on equity (ROE) is projected to increase from -3.0% in 2023 to 14.8% in 2027, reflecting better utilization of equity [3][9].

Core Viewpoint - Dongyangguang Technology Holdings Co., Ltd. has successfully turned around its financial performance in 2024, achieving a revenue of 12.199 billion yuan, a year-on-year increase of 12.40%, and a net profit of 375 million yuan, marking a return to profitability [1][2] Financial Performance - In 2024, the company reported a revenue of 12.199 billion yuan, with a year-on-year growth of 12.40% [1] - The net profit attributable to shareholders was 375 million yuan, compared to a loss in the previous year [1] - The company expects a net profit of 253 million to 323 million yuan for Q1 2025, representing a year-on-year increase of 156.17% to 227.05% [1] Business Segments - The main business segments include electronic components, high-end aluminum foil, chemical new materials, energy materials, and liquid cooling technology [2] - Revenue from electronic components reached 3.396 billion yuan, up 9.94% year-on-year [2] - High-end aluminum foil revenue was 5.191 billion yuan, reflecting a 19.77% increase [2] - Chemical new materials, energy materials, and other businesses generated revenues of 2.704 billion yuan, 354 million yuan, and 84.416 million yuan, respectively [2] Strategic Initiatives - The company has implemented strategic adjustments and new business growth, leading to improved financial performance [1][2] - There has been a significant increase in production capacity utilization in the electronic components sector due to rising demand from data centers and energy storage industries [2] - The company is focusing on large customer strategies, technological innovation, and cost management to enhance product competitiveness [2] Emerging Business Expansion - Dongyangguang is actively expanding into liquid cooling and embodied intelligence sectors [3] - The price of refrigerants has risen significantly, with R32 increasing by 126.09%, positively impacting the company's refrigerant business profitability [3] - The company has established a strategic layout for liquid cooling technologies and is one of the few firms providing comprehensive solutions in this area [3][4] Collaboration and ESG Initiatives - A joint venture has been formed to promote liquid cooling solutions, collaborating with local government for data center projects [4] - The company has invested in embodied intelligence technology, establishing a subsidiary focused on robotic data collection [5] - An ESG report has been released, highlighting the company's commitment to environmental, social, and governance responsibilities [5]

Group 1 - Dongyangguang (600673.SH) released its 2024 annual report on April 10, 2025, with 190 institutional investors holding a total of 1.948 billion shares, representing 64.63% of the total share capital [1] - The top ten institutional investors collectively hold 59.15% of the shares, with a decrease of 1.16 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, six funds reduced their holdings compared to the previous quarter, accounting for a decrease of 1.59% [2] - A total of 175 new public funds were disclosed this period, including notable funds such as Xingquan Trend Investment Mixed (LOF) and Southern CSI 500 ETF [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.20% compared to the previous quarter [2]

广东东阳光科技控股股份有限公司 内部控制审计报告 + 目 录 | 一、内部控制审计报告………………………………………………第 | | 1—2 | 页 | | --- | --- | --- | --- | | 二、附件……………………………………………………………… | 第 | 3-6 | 页 | | (一)本所营业执照复印件………………………………………… | | 第 3 | 页 | | (二)本所执业证书复印件………………………………………… | | 第 4 | 页 | | (三)执业注册会计师资格证书复印件………………………… | 第 | 5-6 | 页 | 内部控制审计报告 天健审〔2025〕11-214 号 广东东阳光科技控股股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了广东东阳光科技控股股份有限公司（以下简称东阳光公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是东阳 ...

广东东阳光科技控股股份有限公司 2024 年度年报审计报告 + 审 计 报 告 天健审〔2025〕11-213 号 广东东阳光科技控股股份有限公司全体股东： 一、审计意见 我们审计了广东东阳光科技控股股份有限公司（以下简称东阳光公司）财务报表， 包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司所有者权益变动表，以及相关财务报表 附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允 反映了东阳光公司 2024 年 12 月 31 日的合并及母公司财务状况，以及 2024 年度的合 并及母公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会 计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国 注册会计师职业道德守则，我们独立于东阳光公司，并履行了职业道德方面的其他责 任。我们相信，我们获取的审计证据是充分、适当的，为发表审计意见提供了基础。 三、关键审计事项 目 录 | 一、审计报告………………………………… ...